Stockscreener 앱 받기
19.82
2.11%
0.41
시장 영업 전:
19.85
0.03
+0.15%
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Will Castle Biosciences Inc. outperform tech stocksMax Yield Daily Selections - mustnews.co.kr
Castle Biosciences Updates Bylaws for Improved Governance - TipRanks
CSTL SEC FilingsCastle Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Price Clustering Detected in Castle Biosciences Inc. StockExit Ready Momentum Stock Watchlist Expanded - beatles.ru
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Castle Biosciences (CSTL) and Regeneron (REGN) - The Globe and Mail
Castle Biosciences Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Castle Biosciences Reports Strong Q2 2025 Results - TipRanks
Barrett Business Reports Q2 GAAP EPS of $0.70, Beating Estimates by $0.01 - AInvest
Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences Maintains Strong Buy Rating with $32 Price Target - AInvest
Castle Biosciences Raises Revenue Guidance Amid Growth and Challenges - AInvest
Robert W. Baird Sticks to Its Buy Rating for Castle Biosciences (CSTL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie, Castle Biosciences, and Regeneron - AInvest
Castle Biosciences’ Earnings Call: Growth Amid Challenges - TipRanks
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates - MSN
Castle Biosciences Reports Strong Q2 2025 Financial Results - MSN
Castle Biosciences Soars 22.52% on Strong Q2 Earnings - AInvest
Castle Biosciences Q2 2025 Earnings Call Highlights: Strong Revenue Growth Despite Challenges - AInvest
Castle Biosciences Inc (CSTL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance
Castle Biosciences Reports Second Quarter 2025 Results - The Manila Times
Castle Biosciences Inc (CSTL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Castle Biosciences Q2 2025 Earnings Exceed Expectations with $86.2M Revenue, $0.16 EPS, and Strong Gross Margin of 77% - AInvest
Castle Biosciences: A Strategic Bet on Personalized Oncology Diagnostics - AInvest
Transcript : Castle Biosciences, Inc., Q2 2025 Earnings Call, Aug 04, 2025 - MarketScreener
Castle Biosciences Outpaces Estimates And Ups Forecast - Finimize
Castle Biosciences Outpaces Expectations With Bright Forecast - Finimize
Earnings call transcript: Castle Biosciences Q2 2025 beats EPS forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Castle Biosciences Q2 2025 beats EPS forecast - Investing.com
Medical testing provider Castle Bio raises annual revenue guidance - MarketScreener
Castle Biosciences Q2 2025 slides: Test volume surges 33% amid declining margins - Investing.com India
Shareholders in Castle Biosciences (NASDAQ:CSTL) have lost 65%, as stock drops 10% this past week - simplywall.st
What drives Castle Biosciences Inc. stock priceMaximize gains with strategic stock entries - Jammu Links News
What is the dividend policy of Castle Biosciences Inc. stockHigh-octane gains - Jammu Links News
What are analysts’ price targets for Castle Biosciences Inc. in the next 12 monthsMaximize portfolio returns with smart trading - Jammu Links News
What catalysts could drive Castle Biosciences Inc. stock higher in 2025Invest smarter with expert trading signals - Jammu Links News
What are Castle Biosciences Inc. company’s key revenue driversOutstanding growth strategies - Jammu Links News
Should I hold or sell Castle Biosciences Inc. stock in 2025Phenomenal capital gains - Jammu Links News
What institutional investors are buying Castle Biosciences Inc. stockMaximize your portfolio’s earning potential - Jammu Links News
When is Castle Biosciences Inc. stock expected to show significant growthRapid portfolio appreciation - Jammu Links News
How volatile is Castle Biosciences Inc. stock compared to the marketGrow your wealth steadily and securely - Jammu Links News
How many analysts rate Castle Biosciences Inc. as a “Buy”Free Stock Selection - Jammu Links News
Castle Biosciences Q2 Earnings Preview: Analysts Expect $-0.50 EPS - AInvest
Castle Biosciences CSTL Q2 2025 Earnings Preview Upside Potential on Raised Revenue Forecast - AInvest
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 26% - 富途牛牛
Published on: 2025-07-30 02:23:31 - metal.it
The True Test of Success - thebossmagazine.com
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Healthcare Innovator Castle Biosciences Reveals Latest Growth Strategy at Major Investment Conference - Stock Titan
What Technical Tools Say About Castle Biosciences Inc. RecoveryConsistent Income Focused Trade List Analyzed - metal.it
1.12%
0.47%
자본화:
|
볼륨(24시간):